{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":22,"n_cols":5,"rows_kept":22,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[16,2,16,3],[17,2,17,3],[19,2,19,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9911009339003321"]
[null,null,"Autore",null,"Ballen Karen"]
[null,null,"Titolo",null,"Clinical Management of Challenges in Allogeneic Stem Cell Transplant / / edited by Karen Ballen"]
[null,null,"Pubbl/distr/stampa",null,"Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025"]
[null,null,"ISBN",null,"3-031-84988-4"]
[null,null,"Edizione",null,"[1st ed. 2025.]"]
[null,null,"Descrizione fisica",null,"1 online resource (430 pages)"]
[null,null,"Collana",null,"Advances in Experimental Medicine and Biology, , 2214-8019 ; ; 1475"]
[null,null,"Disciplina",null,"616.02774"]
[null,null,"Soggetti",null,"Stem cells"]
[{"$nulls":4},"Hematology"]
[{"$nulls":4},"Transplantation of organs, tissues, etc"]
[{"$nulls":4},"Cancer"]
[{"$nulls":4},"Stem Cell Biology"]
[{"$nulls":4},"Transplantation"]
[{"$nulls":4},"Cancer Stem Cells"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Access to Transplant Care and Social Determinants of Health -- Allogeneic Transplantation for Older Adults -- Conditioning Regimen Options -- Graft source choice -- Optimal GVHD Prophylaxis -- Modern era challenges in the clinical management of graft versus host disease -- Acute Myeloid Leukemia Use of Measurable Residual Disease to Improve Outcomes -- Clinical Management of Challenges in Allogeneic Stem Cell Transplant -- Myelofibrosis Timing of Transplantation and Management of Splenomegaly -- Hematopoietic Stem Cell Transplantation in Sickle Cell Disease -- Pharmacological Maintenance Therapies after Allogeneic Hematopoietic Cell Transplantation -- Challenges and opportunities in the care of hematopoietic cell transplant survivors in the modern era."]
[null,null,null,"Sommario/riassunto","The purpose of the book is to focus attention and offer suggestions on controversial and challenging topics in allogeneic stem cell transplant. Over 40,000 allogeneic hematopoietic cell transplants (HCT) are done worldwide each year. Despite advances in allogeneic transplant, the cure rate is only 50-70%, depending on disease and patient factors. The book focuses on key topics such as patient selection, donor selection, conditioning regimens, graft vs. host disease prophylaxis regimens, maintenance strategies, and other topics that affect patient "]
[{"$nulls":4},"outcomes. The authors also discuss access to transplant care. Through dissemination of these topics, we hope to educate health care professionals caring for these patients, and improve patient outcomes. This is an essential resource for transplant physicians, hematologists/oncologists, and advance practice providers. Several of the topics are controversial issues that are discussed “round the table” frequently by transplant teams."]